1. A selective phosphodiesterase 10A inhibitor reduces L-dopa-induced dyskinesias in Parkinsonian monkeys;Beck;Mov. Disord.,2018
2. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use;Bender;Pharmacol. Rev.,2006
3. Phosphodiesterase 1 bridges glutamate inputs with NO- and dopamine-induced cyclic nucleotide signals in the striatum;Betolngar;Cereb. Cortex,2019
4. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap;Calabresi;Lancet Neurol.,2010
5. Davis, R., Riesenberg, R., Laskowitz, D., Guptill, J., Sanders, L., Cooney, J., Satlin, A., O'Brien, J., Duthiel, S., Cruz, S., Hendrick, J., Li, P., Wennogle, L., Glass, S., Pinho, M., Taylor, E., Kozauer, S., Weingart, M., Mates, S., Snyder, G., Vanover, K., 2019. ITI-214, a novel phosphodiesterase I inhibitor for the treatment of Parkinson's disease: results from a phase I/II clinical study. Neurology 92, 15 Supplement P2.8–051.